Soji Kakiuchi

2.4k total citations · 1 hit paper
41 papers, 1.9k citations indexed

About

Soji Kakiuchi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Soji Kakiuchi has authored 41 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Soji Kakiuchi's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (10 papers) and Occupational and environmental lung diseases (9 papers). Soji Kakiuchi is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (10 papers) and Occupational and environmental lung diseases (9 papers). Soji Kakiuchi collaborates with scholars based in Japan, United Kingdom and United States. Soji Kakiuchi's co-authors include Saburo Sone, Seiji Yano, Yasuhiko Nishioka, Masaki Hanibuchi, Hisanori Uehara, Hirokazu Ogino, Yataro Daigo, Tatsuhiko Tsunoda, Wei Wang and Hisatsugu Goto and has published in prestigious journals such as Nature Communications, Cancer Research and Oncogene.

In The Last Decade

Soji Kakiuchi

40 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations

2008 513 citations Seiji Yano, Wei Wang et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Soji Kakiuchi Japan	21	998	910	850	313	153	41	1.9k
Masaki Hanibuchi Japan	22	797 0.8×	863 0.9×	837 1.0×	226 0.7×	256 1.7×	105	1.9k
Dana T. Aftab United States	20	803 0.8×	574 0.6×	882 1.0×	417 1.3×	156 1.0×	45	1.8k
Haruhiro Yukiue Japan	29	839 0.8×	1.1k 1.2×	812 1.0×	352 1.1×	91 0.6×	71	2.0k
Cheng‐long Huang Japan	26	1.3k 1.3×	673 0.7×	973 1.1×	478 1.5×	165 1.1×	68	2.3k
Rosa Caputo Italy	20	1.0k 1.0×	906 1.0×	1.3k 1.6×	355 1.1×	164 1.1×	21	2.3k
Amrita Desai United States	19	657 0.7×	1.1k 1.2×	1.3k 1.5×	359 1.1×	133 0.9×	36	2.3k
S. Gail Eckhardt United States	14	686 0.7×	470 0.5×	779 0.9×	302 1.0×	64 0.4×	46	1.3k
Yoshiyasu Nakamura Japan	25	650 0.7×	398 0.4×	528 0.6×	325 1.0×	160 1.0×	71	1.6k
Maja J.A. de Jonge Netherlands	19	865 0.9×	420 0.5×	848 1.0×	259 0.8×	121 0.8×	40	1.6k
Jean–Louis Fischel France	24	817 0.8×	599 0.7×	1.2k 1.4×	348 1.1×	80 0.5×	62	1.9k

Countries citing papers authored by Soji Kakiuchi

Since Specialization

Citations

This map shows the geographic impact of Soji Kakiuchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Soji Kakiuchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Soji Kakiuchi more than expected).

Fields of papers citing papers by Soji Kakiuchi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Soji Kakiuchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Soji Kakiuchi. The network helps show where Soji Kakiuchi may publish in the future.

Co-authorship network of co-authors of Soji Kakiuchi

This figure shows the co-authorship network connecting the top 25 collaborators of Soji Kakiuchi. A scholar is included among the top collaborators of Soji Kakiuchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Soji Kakiuchi. Soji Kakiuchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kakiuchi, Soji, et al.. (2024). Two Cases of Mycobacterium shinjukuense Pulmonary Disease With a Long-Term Response to Treatment With Clarithromycin, Rifampicin, and Ethambutol. Cureus. 16(1). e52888–e52888.

Ogino, Hirokazu, Masaki Hanibuchi, Satoshi Sakaguchi, et al.. (2018). The clinical features of older patients with lung cancer in comparison with their younger counterparts. Respiratory Investigation. 57(1). 40–48. 4 indexed citations

Hanibuchi, Masaki, Soji Kakiuchi, Shinji Atagi, et al.. (2018). A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease. Lung Cancer. 125. 93–99. 20 indexed citations

Mitsuhashi, Atsushi, Hisatsugu Goto, Takuya Kuramoto, et al.. (2013). Surfactant Protein A Suppresses Lung Cancer Progression by Regulating the Polarization of Tumor-Associated Macrophages. American Journal Of Pathology. 182(5). 1843–1853. 48 indexed citations

Kuramoto, Takuya, Hisatsugu Goto, Atsushi Mitsuhashi, et al.. (2012). Dll4-Fc, an Inhibitor of Dll4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-κB Activity. Molecular Cancer Therapeutics. 11(12). 2578–2587. 41 indexed citations

Hanibuchi, Masaki, Hisatsugu Goto, Takuya Kuramoto, et al.. (2012). SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model. Respirology. 17(6). 984–990. 11 indexed citations

Sato, Seidai, Masaki Hanibuchi, Takuya Kuramoto, et al.. (2012). Macrophage stimulating protein promotes liver metastases of small cell lung cancer cells by affecting the organ microenvironment. Clinical & Experimental Metastasis. 30(3). 333–344. 29 indexed citations

Ogino, Hirokazu, Masaki Hanibuchi, Soji Kakiuchi, et al.. (2011). E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor. Molecular Cancer Therapeutics. 10(7). 1218–1228. 16 indexed citations

Hanibuchi, Masaki, Fumitaka Ogushi, Yoshio Okano, et al.. (2011). A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. Oncology Letters. 2(3). 465–470. 3 indexed citations

10.

Sakaguchi, Satoshi, Hisatsugu Goto, Masaki Hanibuchi, et al.. (2010). Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice. Clinical & Experimental Metastasis. 27(5). 351–359. 9 indexed citations

11.

Hanibuchi, Masaki, Soji Kakiuchi, Seidai Sato, et al.. (2010). The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Cancer Chemotherapy and Pharmacology. 68(2). 497–504. 8 indexed citations

12.

Ogino, Hirokazu, Seiji Yano, Soji Kakiuchi, et al.. (2009). Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. Kanazawa University Repository for Academic Resources (DSpace) (Kanazawa University). 17 indexed citations

13.

Hanibuchi, Masaki, Kenji Ikuta, Seiji Yano, et al.. (2009). A Bone Metastasis Model With Osteolytic and Osteoblastic Properties of Human Lung Cancer ACC-LC-319/bone2 in Natural Killer Cell-Depleted Severe Combined Immunodeficient Mice. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 17(11). 581–591. 15 indexed citations

14.

Yano, Seiji, Wei Wang, Qi Li, et al.. (2008). Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations. Cancer Research. 68(22). 9479–9487. 513 indexed citations breakdown →

15.

Wang, Wei, Yasuhiko Nishioka, Shuji Ozaki, et al.. (2008). HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunology Immunotherapy. 58(6). 967–976. 54 indexed citations

16.

Ogino, Hirokazu, Seiji Yano, Soji Kakiuchi, et al.. (2008). Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. Cancer Letters. 265(1). 55–66. 1 indexed citations

17.

Yamada, Tadaaki, Seiji Yano, Hirokazu Ogino, et al.. (2008). Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA₁ and LPA₂. Cancer Science. 99(8). 1603–1610. 20 indexed citations

18.

Nakataki, Emiko, Seiji Yano, Hisatsugu Goto, et al.. (2006). Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES‐10 cells) highly expressing vascular endothelial growth factor and its receptor. Cancer Science. 97(3). 183–191. 40 indexed citations

19.

Muguruma, Hiroaki, Seiji Yano, Soji Kakiuchi, et al.. (2005). Reveromycin A Inhibits Osteolytic Bone Metastasis of Small-Cell Lung Cancer Cells, SBC-5, through an Antiosteoclastic Activity. Clinical Cancer Research. 11(24). 8822–8828. 39 indexed citations

20.

Kakiuchi, Soji, Yataro Daigo, Nobuhisa Ishikawa, et al.. (2004). Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Human Molecular Genetics. 13(24). 3029–3043. 145 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact